Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
This difference could be due to the collection method of the plasma, which was done in EDTA for our samples while lithium-heparin tubes were used by Naviaux et al.
This extended processing time probably means any metabolites with a short half life will be difficult to measure. I keep hoping that one group will detect increased mast cell mediators but they have a very short half life. Blood needs to be immediately processed and frozen to detect those. The unknown is the unfrozen handling time at Metabolon so maybe they can't be measured anyway.Blood samples were collected in NYC by ME/CFS expert physician Dr. Susan Levine in EDTA
tubes and shipped overnight by FedEx in a Styrofoam box to Cornell University-Ithaca Biotechnology
Building, where plasma was separated from cells by centrifugation at 500 g for 30 min, before being
stored at 80 C until further analysis.
I
I bet Inosine is not showing as a low metabolite because of some methodology issue .
Interesting peaks. I wonder if those are from patients that supplement Inosine. Researchers need to know what medications and supplements study participants are on to interpret these peaks correctly.Here's a chart of raw data for Inosine for this study
How is Metabolon even able to measure Adenosine if it has such a short half-life?????Inosine is an endogenous purine nucleoside that is produced by catabolism of adenosine. Adenosine has a short half-life (approximately 10 s) and is rapidly deaminated to inosine, a stable metabolite with a half-life of approximately 15 h.
So cAMP is meant to be statistically different between controls and patients. However when you plot out the data and give it the eye test you can see there really is not a lot of difference. In my humble non scientific opinion I would prefer a much larger sample size to say for sure that cAMP is statistically different. Hopefully this is where Maureen Hansons NIH grant comes in.Box plot distribution of logged values for metabolites scored as being statistically different between controls (red) and patients (blue) at p < 0.05 and q < 0.15 by the Wilcoxon test.
@Murph Were you able to find Figure S1 and Figure S2?The raw data is available in an excel spreadsheet here. https://www.mdpi.com/2218-1989/8/4/90/htm#app1-metabolites-08-00090 It's in a very easy to use format.
The volcano plot tool combines fold changes and non-parametric testing for an alternative exploration of the data in order to bring in some biological significance to statistical analysis. A total of 7 metabolites stood out when using a fold change threshold of two and raw p < 0.05, while assuming an unequal group variance. Out of the 7, two overlap with the statistically significant metabolites described in the above section, namely heme and IMP.
All the other metabolites identified in the volcano plot had higher abundances in patients compared to controls (Figure S1). These included tauroursodeoxycholate (TUDCA), reported both as a cytoprotective agent and a chemical chaperone; 3-hydroxybutyrylcarnitine 1 and 3-hydroxybutyrate(BHBA), both involved in ketosis, a metabolic process associated with energy and glucose; piperine, an alkaloid found in herbs and spices; and histamine, a compound known to be involved in many aspects of the human body, including local immune responses, acting as a central neurotransmitter and a vasodilator to name a few.
Perfluorooctanesulfonic acid (conjugate base perfluorooctanesulfonate) (PFOS) is an anthropogenic fluorosurfactant and global pollutant. PFOS was the key ingredient in Scotchgard, a fabric protector made by 3M, and numerous stain repellents. It was added to Annex B of the Stockholm Convention on Persistent Organic Pollutants in May 2009.[4] PFOS can be synthesized in industrial production or result from the degradation of precursors. PFOS levels that have been detected in wildlife are considered high enough to affect health parameters, and recently higher serum levels of PFOS were found to be associated with increased risk of chronic kidney disease in the general US population.[5] "This association was independent of confounders such as age, sex, race/ethnicity, body mass index, diabetes, hypertension, and serum cholesterol level."[5][